Sanket Shah Acquires 5,000 Shares of FocalTherics (NASDAQ:FOCL) Stock

FocalTherics (NASDAQ:FOCL) General Counsel Sanket Shah acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average price of $4.75 per share, for a total transaction of $23,750.00. Following the completion of the purchase, the general counsel owned 72,500 shares of the company’s stock, valued at approximately $344,375. This represents a 7.41% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

FocalTherics Stock Down 2.3%

FOCL stock opened at $4.26 on Wednesday. The business has a 50-day moving average of $5.38. The firm has a market capitalization of $159.66 million, a P/E ratio of -4.14 and a beta of -0.04. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79. FocalTherics has a fifty-two week low of $1.30 and a fifty-two week high of $6.40.

FocalTherics (NASDAQ:FOCL) last released its earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.19). FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. The company had revenue of $13.20 million for the quarter. Equities analysts anticipate that FocalTherics will post -0.78 EPS for the current year.

Institutional Trading of FocalTherics

A number of hedge funds and other institutional investors have recently made changes to their positions in FOCL. Flax Pond Capital LLC acquired a new position in shares of FocalTherics in the 4th quarter worth $2,623,000. Leonteq Securities AG purchased a new stake in shares of FocalTherics during the fourth quarter valued at $313,000. Rock Springs Capital Management LP boosted its position in shares of FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after purchasing an additional 91,500 shares during the period. Kovack Advisors Inc. acquired a new position in shares of FocalTherics in the 4th quarter valued at $53,000. Finally, Lido Advisors LLC acquired a new stake in FocalTherics during the 1st quarter worth about $40,000. 62.74% of the stock is currently owned by institutional investors.

Key Headlines Impacting FocalTherics

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: FocalTherics insiders collectively purchased 116,000 shares for approximately $551,000 at $4.75 per share. Buyers included CEO Ryan Rhodes, CFO Kenneth Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and several directors. The coordinated open-market purchases may signal that company leadership views recent weakness as an attractive entry point. FocalTherics insider buying report
• Positive Sentiment: Director Lance Willsey made the largest purchase at 50,000 shares, while CEO Ryan Rhodes bought 21,000 shares. Other executives and directors increased their holdings by roughly 2.8% to 196%, strengthening the insider-buying signal. FocalTherics director transaction filing
• Neutral Sentiment: Recent filings show several institutional investors initiated positions, and institutions collectively own 62.74% of FocalTherics. While this indicates continued professional-investor interest, the disclosed purchases vary considerably in size and do not establish a clear near-term catalyst.
• Neutral Sentiment: A recent article characterized FocalTherics as targeting market leadership following a “record-breaking quarter,” but the available report provides insufficient financial detail to independently assess the claim. FocalTherics market leadership article
• Negative Sentiment: The company’s latest quarterly loss was $0.39 per share, substantially worse than the expected $0.20 loss, on revenue of $13.20 million. FocalTherics also reported a negative net margin of 56.26% and analysts expect a full-year loss of approximately $0.78 per share, keeping profitability and financing risk in focus.
• Negative Sentiment: Analyst opinion is mixed: although some firms maintain Buy or Outperform ratings and a $7.75 consensus target, Piper Sandler rates the stock Neutral with a $4 target, while Wall Street Zen recently downgraded it to Sell. Shares also remain below their 50-day moving average of $5.38, reflecting continued technical weakness.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on FOCL shares. Mizuho set a $15.00 target price on FocalTherics and gave the stock an “outperform” rating in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of FocalTherics in a research report on Tuesday, June 2nd. Piper Sandler reissued a “neutral” rating and issued a $4.00 price objective on shares of FocalTherics in a research note on Friday. Wall Street Zen lowered FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of FocalTherics in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $7.75.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.